Authors


Crystal K. Hodge, PharmD, BCIDP

Latest:

The Pendulum of Progress: Soft Skills in Whole Person Clinical Training

These skills are as critical as ever, and younger clinicians and learners need them to communicate and work professionally.



Takako S. Schaninger, MD

Latest:

Challenges in the Management of Mycobacterium abscessus Complex

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.



Frank J. Palella, MD

Latest:

Supporting Patients With HIV

Advice to community physicians regarding ways to enhance patient-provider relationships and navigate barriers that impact the management of HIV infections.


Ammara Mushtaq, MD

Latest:

Correcting the Lack of Diversity in Clinical Trials With Community-Based Studies

Ammara Mushtaq, MD, discusses the underrepresentation of different races during the pandemic, but also the newer efforts to include and represent these communities in smaller, local studies.


Megan E. Klatt, PharmD, BCIDP, DPLA

Latest:

Updates in the Treatment of Mycobacterium Tuberculosis

The latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.



Philip Giordano, MD

Latest:

In These COVID 19 Times, Can We Reduce Hospitalizations Due to Skin Infections?

Shortages of health care workers and an increase in COVID-19 cases has put a severe strain on the health care system. Thus, the opportunity to reduce the hospitalizations for other conditions and expand outpatient treatment opportunities should be welcomed.


Laura Selby, DO

Latest:

Reducing Peripheral Venous Catheter Infections

Lack of data may mean bloodstream infections caused by PVCs are an overlooked cause of morbidity in hospitalized patients.


Karine G. Le Roch, PhD

Latest:

Kalihinol Analog Targets Apicoplast Function In Malaria Treatment

Karine G. Le Roch, PhD, discussed her research on a kalihinol analog that combats drug resistance in malaria, emphasizing the need for innovative treatments in the context of climate change and rising transmission rates.


Rebecca Fallis, MD

Latest:

Final Diagnosis: Pott Puffy Tumor With Subdural Empyema

A rare case of Pott puffy tumor occurs in an atypical patient with no risk factors, likely due to untreated sinus infection.


James F. Cummings, MD

Latest:

Evaluating Safety and Efficacy of Vaxart's Oral Vaccine's Impact on COVID-19 Variants

Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.


Pamela Bailey, DO, MPH

Latest:

“Triple Therapy” Facing Triple Threat

Clinicians provide an overview of intraamniotic infections and offer treatment strategies for these challenging infections.


Eli Goshorn, MD

Latest:

The Underlying Threat of Multidrug-Resistant Pathogens in the COVID-19 Era

Over half of patients admitted with positive SARS-CoV-2 testing received antibiotics, but evidence of bacterial infection is uncovered in far fewer cases. We may already be seeing the effects of antibiotic overprescribing.


Esther O. Fasanmi, PharmD, BCIDP, BCPS, AAHIVP

Latest:

Biden Administration Unveils HCV Initiative: A Significant Step Towards Public Health

The federal government is working to provide greater access to testing and treatment.


Jessica Foley, PharmD, BCIDP

Latest:

Shifting to Shorter Courses of Antibiotic Therapy for Common Pediatric Infections

In the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.


Tim Smith

Latest:

Investigational Hepatitis D Therapy Well-Tolerated, Safe for Chronic Disease at Week 48

In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.


Jeffrey Lipman, MD, DMed(Res)

Latest:

Sepsis Awareness Month: Highlighting the Findings from BLINGIII

Continuous antibiotic infusions show positive results and may improve outcomes for patients with severe sepsis.


Ami Patel, PhD

Latest:

Differentiating Between DNA and mRNA Platforms

Ami Patel, PhD, provides insights on both technologies and how her research center, the Wistar Institute, is involved in DNA vaccine and monoclonal antibody research.


Jaclyn O’Connor, PharmD

Latest:

Sticking It to COVID-19: The Expansion of the Pfizer-BioNTech Vaccine EUA

A review of the data and circumstances that led to authorization in children ages 5 to 11 years.


Matthew Girgis, PHARMD, BCIDP

Latest:

So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.


James Donovan, MD

Latest:

Final Diagnosis: Donor-Derived Staphylococcus Iugdunensis Endocarditis of Transplanted Heart

"This case gives uncomfortable insight into a gap in early detection of infections in immunocompromised, high-risk patient populations. "


Abigail Brooks, MA

Latest:

Injection Drug Use and Immunodeficiency Linked to Failed Hepatitis C Treatment in People with HIV

Lower CD4+ cell counts, HCV genotype 4, and recent injection drug use were linked to unsuccessful DAA treatment in people with HCV and HIV.


Valencia Oglesby, DO

Latest:

Preparing for the Next Long-acting Antiretrovirals

Clinicians can make room for infrequent treatment options as patients enjoy their daily lives.


Steven Levine

Latest:

The Business Sector's Advocacy to Maintain Funding for HIV Prevention, Research, Treatment

A coalition of employers, the US Business Action to End HIV, sent a letter to Congress outlining the continued need for support from the federal government.



Jared Baeten, MD, PhD

Latest:

Gilead and Merck Report Successful Phase 2 Results for Investigational Once-Weekly HIV Treatment

The combination of the antiviral agents islatravir and lenacapavir demonstrates both efficacy and safety, leading to advancement into Phase 3 trials.



Paul Feuerstadt, MD

Latest:

Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile Infections

To close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.

© 2025 MJH Life Sciences

All rights reserved.